NPR-1激动剂XXB750治疗难治性高血压的2期随机试验
这项2期随机双盲安慰剂对照试验在189例难治性高血压患者中评估每月皮下注射XXB750(30-240mg)对24小时收缩压的影响。XXB750虽剂量依赖性增加cGMP,但12周时24小时收缩压较基线无显著剂量依赖性变化,各剂量降压效果均不优于安慰剂。
要点
- XXB750在难治性高血压患者中未显示优于安慰剂的降压效果。
- XXB750剂量依赖性增加cGMP,提示靶点结合良好但血压无响应。
- XXB750组不良事件数值上高于安慰剂组。
核心结论
- XXB750对难治性高血压患者24小时动态收缩压呈中性效应,尽管cGMP水平呈稳健剂量依赖性升高提示靶点作用明确。
研究设计与样本
- 2期多中心随机双盲安慰剂对照试验,纳入189例难治性高血压患者,基线24小时动态血压148/81±11/10 mmHg。
- 难治性高血压定义为使用3或4种指南指导降压药后24小时收缩压仍≥135 mmHg。
- XXB750设30mg、60mg、120mg、240mg四个剂量,每月皮下注射一次,于基线、第4周和第8周给药。
- 主要终点为第12周24小时平均收缩压自基线的变化相对安慰剂的剂量-反应关系。
主要发现
- XXB750各组血浆浓度剂量依赖性升高,第12周血浆和尿cGMP浓度也剂量依赖性升高。
- 第12周24小时平均收缩压自基线变化无显著剂量依赖性,各剂量XXB750降压效果均不优于安慰剂。
- 动态血压变化不受抗药抗体产生的影响。
- XXB750组尿钠排泄自基线无变化,但血浆肾素水平小幅升高。
- XXB750组不良事件数值上高于安慰剂组。
临床怎么用
- XXB750虽靶点结合明确,但当前证据不支持用于难治性高血压的降压治疗。
- 难治性高血压患者仍需依据指南优化现有降压药物联合方案。
局限性
- 原文未报告样本量计算、效应量及置信区间等详细统计信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: XXB750 is a potent and long-acting human monoclonal antibody agonist of the natriuretic peptide receptor-1 (NPR-1), the receptor for atrial natriuretic peptide and B-type natriuretic peptide. Activation of NPR-1 may lower blood pressure (BP) in patients with resistant hypertension through increases in the second messenger cyclic guanosine monophosphate. OBJECTIVES: The aim of this study was to determine the effect of NPR-1 agonism on 24-hour BP. METHODS: This phase 2, multicenter, randomized, double-blind, placebo-controlled trial evaluated 4 once-monthly subcutaneous doses of XXB750 (30 mg, 60 mg, 120 mg, and 240 mg) administered at baseline, week 4, and week 8 in patients with resistant hypertension. Resistant hypertension was defined as 24-hour systolic BP (SBP) ≥135 mm Hg despite treatment with 3 or 4 guideline-directed antihypertensive agents. The primary endpoint was the dose-response relationship of XXB750 vs placebo in reducing the mean 24-hour SBP from baseline to week 12. RESULTS: The study population (N = 189) had a mean age of 61 years, was 69% male, 61% White, 20% Asian, and 14% Black/African American, and had a baseline mean 24-hour ambulatory BP of 148/81 ± 11/10 mm Hg. Plasma concentrations of XXB750 dose-dependently increased in the XXB750 groups, and XXB750 dose-dependently increased plasma and urine cyclic guanosine monophosphate concentrations by week 12. However, paradoxically, there was no significant dose-dependent change from baseline in mean 24-hour SBP at week 12. In fact, none of the doses of XXB750 had a greater BP-lowering effect than placebo. Changes in ambulatory BP were not affected by the development of anti-drug antibodies. Although there were no changes from baseline in urinary sodium excretion, there were small increases in plasma renin levels in the XXB750 groups. Adverse events with XXB750 were numerically higher than with placebo. Adherence to background antihypertensive medications, assessed by drug assays in 88 patients with available plasma samples, was consistent across all treatment groups at both baseline and week 12. CONCLUSIONS: XXB750, an NPR-1 agonist, had a neutral effect on 24-hour ambulatory SBP in patients with resistant hypertension, despite showing a robust dose-response relationship for engagement of the target of pharmacologic action as indicated by increases in cyclic guanosine monophosphate levels. (An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients; NCT05562934).
引用
- White WB, Azizi M, Ferdinand K, et al. Natriuretic Peptide Receptor-1 Agonist for Resistant Hypertension: A Randomized Phase 2 Trial. J Am Coll Cardiol. 2026. PMID: 41563174. doi:10.1016/j.jacc.2025.11.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。